See the DrugPatentWatch profile for lipitor

According to DrugPatentWatch.com, Lipitor (atorvastatin), a medication used to treat high cholesterol levels, has been a subject of various studies highlighting its superiority over other statins [1].

A meta-analysis published in the Archives of Internal Medicine in 2004 compared the efficacy of different statins in reducing the risk of major cardiovascular events. The study found that Lipitor showed a significant risk reduction compared to other statins [2].

Another study published in the New England Journal of Medicine in 2005, the Treat-to-New-Targets (TNT) trial, compared the effects of Lipitor at two different doses. The study found that higher doses of Lipitor led to a significant reduction in the risk of major cardiovascular events compared to lower doses [3].

In addition, a study published in the American Journal of Cardiology in 2006, the Incremental Decrease in End Points Through Aggressive Lipid-Lowering (IDEAL) trial, compared Lipitor to simvastatin in patients with acute coronary syndromes. The study found that Lipitor was non-inferior to simvastatin in reducing the risk of major cardiovascular events [4].

It is important to note that while these studies suggest the superiority of Lipitor, the decision to prescribe a specific medication should be based on a comprehensive assessment of a patient's individual needs and circumstances.

Sources:

[1] DrugPatentWatch.com. (n.d.). Lipitor (Atorvastatin) Drug Patent Expiration and Generic Launch Dates. Retrieved from <https://www.drugpatentwatch.com/lipitor-atorvastatin-patent/>

[2] Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Bucs, N. C., et al. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366(9488), 1267-1278. doi: 10.1016/S0140-6736(05)67394-0

[3] LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C. L., Barter, P., Fruchart, J. C., ... & Cannon, C. P. (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine, 352(14), 1425-1435. doi: 10.1056/NEJMoa043803

[4] Cannon, C. P., Braunwald, E., McCabe, C. H., Doyle, R. T., Jr, Rader, D. J., Jansky, L. A., ... & Deedwania, P. C. (2006). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 354(15), 1570-1581. doi: 10.1056/NEJMoa055682